Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGD | P52209 | 4/20 | 0.45 |
| ▸ | PGK1 | P00558 | 1/20 | 0.45 |
| ▸ | PGK2 | P07205 | 1/20 | 0.45 |
| ▸ | MPI | P34949 | 1/20 | 0.42 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.41 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5297305 | 1.00 | PGD (0.45) | PGDPGK1PGK2MPILPAR1 | |
| SCHEMBL19462882 | 0.84 | PGK1 (0.43) | PGDPGK1PGK2MPILPAR1 | |
| SCHEMBL680243 | 0.84 | PGK1 (0.43) | PGDPGK1PGK2MPILPAR1 | |
| SCHEMBL3447040 | 0.84 | PGK1 (0.43) | PGDPGK1PGK2MPILPAR1 | |
| SCHEMBL17338080 | 0.84 | PGK1 (0.43) | PGDPGK1PGK2MPILPAR1 | |
| SCHEMBL5594382 | 0.82 | ENPP2 (0.50) | PGDPGK1PGK2MPILPAR1 | |
| SCHEMBL14930899 | 0.80 | PGK1 (0.38) | PGDPGK1PGK2MPILPAR1 | |
| SCHEMBL25335730 | 0.77 | PGK1 (0.38) | PGDPGK1PGK2MPILPAR1 | |
| SCHEMBL7328567 | 0.77 | PGD (0.58) | PGDPGK1PGK2LPAR1LPAR3 | |
| SCHEMBL1525053 | 0.77 | PGK1 (0.47) | PGDPGK1PGK2MPILPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318700-B2 | Lung-targeted drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120122818-A1 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-17 | — | — | US | disclosed |
| US-8101745-B2 | Conjugate cidofovir, idoxuridine, vidarabine, trifluridine, acyclovir, famciclovir penciclovir, valacyclovir, ganciclovir, antiviral, antimicrobial, cancer drug of interest to glycerol ethers or glycerol phosphate ethers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080221061-A1 | Lung-Targeted Drugs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-09-11 | — | — | US | disclosed |
| EP-1831235-A2 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006066074-A2 | LUNG-TARGETED DRUGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221061-A1 | Lung-Targeted Drugs | DGKG, GK, PHOSPHO1 | PGD 372/4885PGK1 138/4885PGK2 109/4885 |
| US-20120122818-A1 | LUNG-TARGETED DRUGS | DGKG, GK, PHOSPHO1 | PGD 372/4885PGK1 138/4885PGK2 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.